Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.94 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.94 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRND | Q07001 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061045 | 0.97 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7ALDH1A1 | |
| SCHEMBL5655866 | 0.94 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7CHRNG | |
| SCHEMBL6350076 | 0.92 | CHRNB2 (0.91) | CHRNB2CHRNA4CHRNA1CHRNA7ALDH1A1 | |
| SCHEMBL5335 | 0.90 | CHRNB2 (0.87) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNB4 | |
| SCHEMBL3538787 | 0.90 | CHRNB2 (0.87) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNB4 | |
| SCHEMBL29507540 | 0.90 | CHRNB2 (0.87) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNB4 | |
| Hydrochloric Acid SCHEMBL9066315 | 0.89 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNA7ALDH1A1CHRNB4 | |
| SCHEMBL30317106 | 0.84 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNA1CHRNA7CHRNG | |
| SCHEMBL7494217 | 0.84 | CHRNB2 (0.75) | CHRNB2CHRNA4CHRNA1CHRNA7ALDH1A1 | |
| SCHEMBL6352432 | 0.81 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNA1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267739-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2010-10-21 | — | — | US | disclosed |
| US-7307087-B2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH A/S (DK) | 2007-12-11 | — | — | US | disclosed |
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | OLSEN GUNNAR M | 2007-11-15 | — | — | US | disclosed |
| EP-1757600-A2 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NeuroSearch A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | disclosed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265241-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | TAAR5, CHRNA5, CHRNA4 | CHRNB2 15/4885CHRNA4 3/4885CHRNA1 6/4885 |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | TAAR5, CHRNA5, CHRNA4 | CHRNB2 15/4885CHRNA4 3/4885CHRNA1 6/4885 |
| US-20100267739-A1 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | CHRNA10, CHRNA2, CHRNA7 | CHRNB2 14/4885CHRNA4 5/4885CHRNA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.